- New ETFs
- Bond ETFs
- Currency ETFs
- Emerging Market ETFs
- Commodity ETFs
- Broad U.S. Equity ETFs
- Sector ETFs
- Specialty ETFs
Human Genome Sciences Up 22% In The Pre-Market
Recent Articles by Benzinga Staff
- Ford At A 5 Year High After Moody's Raises Rating On Ford
- Rising Interest Rates Bullish Or Bearish For Gold?
- E*Trade's February DARTs Take a Dive (ETFC)
- Jesup Narrows Loss Estimates For United (UAUA)
- Recovery Act Program Provides $11 Billion to Build Schools, Create Jobs Across the Country
Company News
- CLARCOR (CLC) Falls 3% In After Hours Trading
- GameStop Earnings Preview (GME)
- FedEx Earnings Preview (FDX)
- Banks Charged With Fraud Over Sale Of Derivatives To The City Of Milan (DB, UBS, JPM)
- Nike, Inc. (NKE) Reports Third-Quarter Results
Pre-Market Outlook
- Propping Continues As Shady Activity Seems To Ensure Market Does Not Fall. (NYSE:SPY), (NYSE:DIA)
- United Airlines Is Descending This Morning As Oil Rises (NASDAQ:UAUA), (NYSE:LUV)
- US Stock Futures Signal Gains
- Benzinga’s Top Pre-Market Losers (CSKI, ERIC, HGSI, EROC)
- Benzinga’s Top Pre-Market Gainers (PLCM, ADSK, MDCO, GNVC)
Price Target
- Aerospace & Defense Industry Update (LLL, BA, RTN, SPR, ESL)
- ATHN Has Strong Long Term Outlook
- OpenTable Inc.’s (OPEN) Price Target Raised
- MYR Group Inc.’s (MYRG) Price Target Raised
- Bank of America (BAC) To Benefit From 4Cs
FDA
- FDA Approves Medtronic (MDT) Diabetes Management System
- Boston Scientific Corporation (BSX) Options Active On Positive FDA Data
- Boston Scientific Corp. Halts Sale Of ICDs (BSX)
- Amylin Shooting Higher
- Medtronic (MDT) Gets FDA Approval For Epilepsy Treatment
Movers
- CLARCOR (CLC) Falls 3% In After Hours Trading
- Blockbuster (BBI) On Brink of Bankruptcy
- CIT Group Inc. (CIT) To Attract Selling On Further Rise
- TARP Repayments, Rating Upgrades Give Financials A Facelift (HIG, DFS, UNM, LNC, GGP, SPG, CIT)
- Fuqi International Inc. (FUQI) Moves Into Bearish Zone On Charts
Analyst Ratings
Posted on 11/02/09 at 7:54am by Benzinga Staff
Human Genome Sciences (Nasdaq: HGSI) is trading up 22% in the pre-market on news that it and GlaxoSmithKline PLC (NYSE: GSK) announced that BENLYSTA™ (belimumab) met the primary endpoint in BLISS-76, the second of two pivotal Phase 3 trials in seropositive patients with systemic lupus erythematosus.
In August 2006, HGS and GSK entered into a definitive co-development and co-commercialization agreement under which HGS has responsibility for conducting the belimumab Phase 3 trials, with assistance from GSK. The companies will share equally in Phase 3/4 development costs, sales and marketing expenses, and profits of any product commercialized under the current agreement.
Leerink Swann raised its price target on Human Genome Sciences from $30 to $40 after hear about the new Lupus drug data.
Bookmark/Search this post with:
Related Articles
- Thomas Weisel Partners More Than Double InterMune (ITMN) Price Target To $55
- Salix Pharmaceuticals (SLXP) Shares Up Nearly 20%
- XenoPort (XNPT) Shares Fall 65% After FDA Rejection
- Needham Urges Buy CBS Corp (CBS) Ahead Of Earnings Report
- Leerink Swann Raises Inspire Pharmaceuticals (ISPH) Price Target To $10
Today's Trading Ideas
Featured Articles
Related News from the Stock Market
- Human Genome Sciences (HGSI) CFO TO Quit In March
- Human Genome Sciences (HGSI) Looks Forward To A Promising Year
- Human Genome Sciences CEO On CNBC (HGSI)
- Cutting Edge Biotech Companies Human Genome Sciences (HGSI) and Dendreon Corp. (DNDN) Are Poised To Go Higher
- Black And Decker and Avis Up As US Stocks Rise (BDK, SWK, HGSI, CAR, F, CIT)
There are 0 comments
Please note that comments may take up to one hour before they get published on the site. Please check back later to see your comments.
Post new comment
Receive Benzinga's Best 2010 Stock Idea!
